These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10071548)

  • 41. [Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years wi alfuzosin in general practice. BPH Group in General Practice].
    Lukacs B; Grange JC; Comet D; Mc Carthy C
    Prog Urol; 1999 Apr; 9(2):271-80. PubMed ID: 10370951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Italian Alfuzosin Co-Operative Group.
    Martelli A; Pacifico P; Casadei G
    Eur Urol; 1993; 24 Suppl 1():28-33. PubMed ID: 7687556
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The efficacy of alfuzosin (dalfaz) in patients with benign prostatic hyperplasia].
    Tkachuk VN; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (2):38-40. PubMed ID: 9577703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice.
    Lukacs B; Grange JC; McCarthy C; Comet D
    Eur Urol; 1998; 33 Suppl 2():28-33. PubMed ID: 9556193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
    Lee M
    Am J Health Syst Pharm; 2003 Jul; 60(14):1426-39. PubMed ID: 12892027
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Sánchez-Chapado M; Guil M; Badiella LI; Fernández-Hernando N; Alfaro V
    BJU Int; 2000 Sep; 86(4):432-8. PubMed ID: 10971267
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Efficacy of an alpha-blocker, alfuzosin, on urinary disorders in men with prostatic adenoma. Intermediate results of a European multicenter study].
    Jardin A
    Ann Urol (Paris); 1988; 22(5):333-40. PubMed ID: 2462402
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
    Kaplan SA; Gonzalez RR; Te AE
    Eur Urol; 2007 Jun; 51(6):1717-23. PubMed ID: 17258855
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
    Lukacs B; Leplège A; Thibault P; Jardin A
    Urology; 1996 Nov; 48(5):731-40. PubMed ID: 8911517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.
    Lukacs B; Grange JC; Comet D
    Urology; 2000 Apr; 55(4):540-6. PubMed ID: 10736498
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group.
    Brawer MK; Adams G; Epstein H
    Arch Fam Med; 1993 Sep; 2(9):929-35. PubMed ID: 7509243
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
    Rosen R; Seftel A; Roehrborn CG
    Int J Impot Res; 2007; 19(5):480-5. PubMed ID: 17717526
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
    Elhilali MM; Ramsey EW; Barkin J; Casey RW; Boake RC; Beland G; Fradet Y; Trachtenberg J; Orovan WL; Schick E; Klotz LH
    Urology; 1996 Mar; 47(3):335-42. PubMed ID: 8633398
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. QOL BPH Study Group in General Practice.
    Lukacs B; McCarthy C; Grange JC
    Eur Urol; 1993; 24 Suppl 1():34-40. PubMed ID: 7687557
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Alfuzosin in benign prostatic hyperplasia. A new principle is evaluated. Report of a study].
    Fortschr Med Suppl; 1995; 166():1-12. PubMed ID: 7537599
    [No Abstract]   [Full Text] [Related]  

  • 57. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
    Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
    Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial.
    Lapitan MC; Acepcion V; Mangubat J
    J Int Med Res; 2005; 33(5):562-73. PubMed ID: 16222890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Our experience with the treatment of benign prostatic hyperplasia (BPH) with tamsulosin.
    Cervenakov I; Fillo J
    Bratisl Lek Listy; 2001; 102(3):138-41. PubMed ID: 11433602
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The efficacy and safety of a new once-a-day formulation of an alpha-blocker.
    Van Kerrebroeck PE
    Eur Urol; 2001 Mar; 39 Suppl 6():19-26. PubMed ID: 11306897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.